Lung-disease drug rentosertib shows potential aging reversal in IPF trial

A small study of rentosertib, an experimental drug for idiopathic pulmonary fibrosis, found biomarkers suggesting participants appeared biologically 3–4 years younger across multiple aging clocks. Researchers caution the result is preliminary, based on 42 patients over 12 weeks, and does not prove actual aging reversal or longer life. Larger, longer trials are needed, including a phase 3 study in China; side effects were generally manageable.